通心络对急性冠脉综合征患者PCI术后的干预作用

Tongxinluo Intervention of Patients with Acute Coronary Syndrome after PIC Surgery

目的:观察通心络对急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后的干预作用。方法:将80例ACS患者随机分为两组,通心络组40例,对照组40例,对照组PCI术后常规服用阿司匹林、氯吡格雷、β受体阻滞剂、硝酸酯类、血管紧张素转换酶抑制剂。通心络组在西医常规用药基础上给予通心络胶囊,4粒/次,3次/d,疗程3个月。结果:两组TC、TG、LDL-C、hs-CRP均降低(P<0.05)HDL-C无明显变化(P>0.05)。与对照组相比,通心络组降低明显(P<0.05),中医证候明显改善,严重心血管事件明显降低。结论:PCI术后在常规治疗的基础上加入通心络胶囊,可明显降低ACS患者血脂、hs-CRP水平,改善中医证候,减少严重心血管事件的发生。

Objective：Effects of Tongxinluo on the intervention effect of percutaneous coronary intervention in patients with acute coronary syndrome after. Method 80 cases of ACS patients were randomly divided into two groups, Tongxinluo group in 40 cases, a control group of 40 cases,Control group PCI routine postoperative aspirin, clopidogrel, beta blockers, nitrates, angiotensin converting enzyme inhibitors.Given Tongxinluo capsule in conventional western medicine on the basis of the treatment of Tongxinluo group, 4 capsules each time, three times a day, a course of 3 months. Result：Two groups of TC, TG, LDL-C, hs-CRP were decreased （P〈0.05）, HDL-C had no significant change （P〉0.05）. Compared with the control group, tongxinluo group decreased significantly （P〈0.05）, syndrome of traditional Chinese Medicine significantly improved, serious cardiovascular events decreased significantly. Conclusion After PCI added Tongxinluo Capsule on the basis of conventional therapy, can significantly reduce the blood lipid level with hs-CRP in ACS patients,improve the TCM Syndrome, reduce the incidence of serious cardiovascular events.